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Interleukin-8 has long been recognized to have anti-inﬂammatory activity, which has been established in various models of
infection, inﬂammation, and cancer. Several cell types express the receptor for the cytokine IL-8 and upon its recognition
produce molecules that are active both locally and systemically. Many diﬀerent types of cells, in particular monocytes, neutrophils,
epithelial, ﬁbroblast, endothelial, mesothelial, and tumor cells, secrete IL-8. Increased expression of IL-8 and/or its receptors has
been characterized in many chronic inﬂammatory conditions, including psoriasis, ARDS, COPD, and RA as well as many cancers,
and its upregulation often correlates with disease activity. IL-8 constitutes the CXC class of chemokines, a potent chemoattractant
and activator of neutrophils and other immune cells. It is a proangiogenic cytokine that is overexpressed in many human cancers.
Therefore, inhibiting the eﬀects of IL-8 signaling may be a signiﬁcant therapeutic intervention.
1.Introduction
IL-8 is secreted by multiple cell types, including monocytes,
neutrophils, epithelial, ﬁbroblast, endothelial, mesothelial,
and tumor cells. It is released from several cell types in
response to an inﬂammatory stimulus [1]. IL-8 plays an
important role in inﬂammation and wound healing [2]
and has a capacity to recruit T cells as well as nonspeciﬁc
inﬂammatory cells into sites of inﬂammation by activating
neutrophils [3]. It also stimulates α-smooth muscle actin
production in human ﬁbroblasts [4]. Furthermore, IL-8 is
chemotactic for ﬁbroblasts, accelerates their migration, and
stimulates deposition of tenascin, ﬁbronectin, and collagen
I during wound healing in vivo [4]. This paper summarizes
current knowledge on the central role of IL-8 in diﬀerent
pathologies. The experimental results and questions posted
in research work on IL-8 are covered here, and the potential
roles of IL-8 as part of a complex cytokine network in wound
healing, angiogenesis, and several cancers are discussed
here.
2. Expressionof IL-8 in Immune System
Inmanycelltypes,thesynthesisofIL-8isstronglystimulated
byIL-1andTNF-α.Inhumanskinﬁbroblasts,theexpression
of IL-8 is enhanced by leukoregulin. The synthesis of IL-
8 is induced also by phytohemagglutinins, concanavalin A,
double-stranded RNA, phorbol esters, sodium urate crystals,
viruses, and bacterial lipopolysaccharides. The expression of
IL-8 from resting and stimulated human blood monocytes is
upregulated by IL-7 [5].
In chondrocytes, the synthesis of IL-8 is stimulated by
IL1-β,T N F - α, and bacterial lipopolysaccharides. In human
astrocytes, the synthesis and secretion of IL-8 is induced by
IL-1 and TNF-α. Glucocorticoids, IL-4, TGF-β, inhibitors2 International Journal of Inﬂammation
of 5 lipoxygenase, and 1.25(OH)2 vitamin D3 inhibit
the synthesis of IL-8. IL-8 is constitutively and commonly
produced by various carcinoma cell lines, and this synthesis
may be related to the elevation of serum IL-8 in patients
with hepatocellular carcinoma. In epithelial, endothelial,
and ﬁbroblastic cells, secretion of IL-8 is induced by IL-17
[6].
3. ProteinCharacteristics
IL-8 is an 8.4kDa nonglycosylated protein produced by pro-
cessing of a precursor protein of 99 amino acids belonging
to the CXC subfamily of chemokines which is characterised
by two essential cysteine residues, separated by a third
intervening amino acid [7, 8]. There are two major forms
of IL-8, that are the 72-amino acid monocyte-derived form,
predominant in cultures of monocytes and macrophages,
and the endothelial form which has ﬁve extra N-terminal
amino acids, predominating in cultures of tissue cells such
as endothelial cells and ﬁbroblasts [9, 10].
Longer forms of IL-8 (79 and 77 amino acids) and
shorter forms (69 amino acids) have been isolated also
from conditioned medium of lymphocytes stimulated with
bacterial lipopolysaccharides, ﬁbroblasts stimulated by IL-
1 or TNF, and polyI: C-stimulated endothelial cells. The
predominantformofIL-8producedbyendothelialcells(and
also by anchorage-dependent cells and human glioblastoma
cells) is the 77-amino acid variant. IL-8 (6–77) has a 5–
10-fold higher activity on neutrophil activation, IL-8 (5–
77) has increased activity on neutrophil activation, and
IL-8 (7–77) has a higher aﬃnity to receptors CXCR1
and CXCR2 as compared to IL-8 (1–77), respectively
[11].
4. IL-8Structure
The human IL-8 gene (SCYB8) has a length of 5.1kb and
maps to human chromosome 4q12-q21. The mRNA consists
of a 101-base 5 untranslated region, an open reading frame
of 297 bases and a long 3 untranslated region of 1.2kb. The
5 ﬂankingregionoftheIL-8genecontainspotential binding
sites for several nuclear factors including activation factor-
1, activation factor-2, IFN regulatory factor-1, hepatocyte
nuclear factor-1, a glucocorticoid-responsive element, and a
heat shock element [12, 13].
5.IL-8andReceptors
IL-8 receptors are a member of a G-protein-coupled receptor
protein family. There are at least two diﬀerent IL-8 receptor
types. The type 1 receptor speciﬁcally binds IL-8 (Kd =
0.8–4nM). The type 2 receptor (Kd for IL-8 = 0.3–2nM)
also binds the IL-8-related factors like MGSA (melanoma
growth stimulatory activity), GRO, MIP-2 (macrophage
inﬂammatory protein), and NAP-2 (neutrophil-activating
protein-2). Both receptor genes map to human chromosome
2q35 [13–15].
6. Biological Functions and Expressionof IL-8
The activities of IL-8 are not species speciﬁc. Human IL-
8 is also active in animal cells. The biological activities of
IL-8 resemble those of a related protein, NAP-2 (neutrophil-
activating protein-2). It diﬀers from all other cytokines in
its ability to speciﬁcally activate neutrophil granulocytes
where it causes a transient increase in cytosolic calcium
levels and the release of enzymes from granules. IL-8 also
enhances the metabolism of ROS (reactive oxygen species)
and increases chemotaxis and the enhanced expression of
adhesion molecules [16].
IL-8 alone does not release histamines. It actually
inhibits histamine release from human basophils induced
by histamine-releasing factors, CTAP-3 (connective tissue
activating protein-3), and IL-3 [17]. IL-8 is involved also in
pain meditation [18]. The intravenous administration of IL-
8 in baboons causes a severe granulocytopenia followed by
granulocytosis which persists as long as suﬃcient IL-8 levels
are maintained [19].
IL-8 is chemotactic for all known types of migratory
immune cells. IL-8 inhibits the adhesion of leukocytes
to activated endothelial cells and therefore possesses anti-
inﬂammatory activities. The 72-amino acid form of IL-8 is
approximately tenfold more potent in inhibiting adhesion of
neutrophils than the 77-amino acid variant [20].
IL-8 is a mitogen for epidermal cells, and in vivo it
strongly binds to erythrocytes. This absorption may be of
physiological importance in the regulation of inﬂamma-
tory reactions since IL-8 bound to erythrocytes no longer
activates neutrophils. Macrophage-derived IL-8 supports
angiogenesis and plays role in disorders such as rheumatoid
arthritis, tumor growth, and wound healing that critically
depend on angiogenesis [21].
Simonet et al. (1994) have studied transgenic mice
overexpressing IL-8. Elevated serum IL-8 levels were found
to correlate with increases in circulating neutrophils and
decreases in L-selectin expression on the surface of blood
neutrophils. The accumulation of neutrophils was observed
in the microcirculation of the lung, liver, and spleen. Neu-
trophil extravasation, plasma exudation, or tissue damage
was absent [22].
IL-8 has been implicated in a number of inﬂammatory
diseases, such as CF [23], ARDS (adult respiratory distress
syndrome) [24], COPD (chronic obstructive pulmonary
disease), and asthma [25]. The airway epithelium is one of
several sources of IL-8 in the airway, and it serves as a barrier
against invading microorganisms. Airway epithelial release
of IL-8 contributes to host defense by promoting neutrophil
chemotaxis and airway inﬂammation [26].
7.ClinicalSigniﬁcance
Inﬂammation is the single greatest cause of pain. The
ﬁrst inﬂammatory mediators recognized to have potent
hyperalgesic properties was bradykinin [27], since then
a host of inﬂammatory medicators have been identiﬁed
which can produce hyperalgesia, including prostaglandins,International Journal of Inﬂammation 3
leukotrienes,serotonin,adenosine,histamine,IL-1,IL-8,and
NGF (nerve growth factor).
Cytokines are produced by leukocytes in response to
exposure to bacterial toxins or to inﬂammatory medicators
[28]. IL-8 has also been found to produce a sympathetic-
dependent hyperalgesia which does not appear to be medi-
cated by prostaglandin [18, 29].
IL-8 was shown to be angiogenic factor in 1992 [21,
30]. Kitadai et al. Found high levels of IL-8 in six of
eight carcinoma cells and lines and 32 of 39 gastric carci-
noma specimens as compared to normal mucosal control.
The levels of IL-8 correlated strongly with the specimen
vascularity [31]. IL-8 was shown to be major inducer of
neovascularisation of squamous cell carcinoma by lingen et
al. [32]. IL-8 also plays a signiﬁcant role in other cancer by
mediating angiogenesis and tumorigenesis. IL-8 is produced
by a wide panel of human cancer cells including colon [10],
melanoma [33], prostate [34], ovary [35, 36], or breast [37–
40].
7.1. IL-8 and Inﬂammatory Diseases
7.1.1. Proinﬂammatory Eﬀects of IL-8. IL-8 is an oxida-
tive stress-responsive proinﬂammatory chemokine, released
from epithelial cells following particle-induced oxidative
stressleadingtoneutrophilinﬂuxandinﬂammation[41,42].
IL-8isapotentchemoattractantandactivatorofneutrophils,
the transcription of which is NF-κBd e p e n d e n t[ 43].
Proinﬂammatory stimuli are considered to be a major
regulator of IL-8 levels in response to injury. IL-8 is involved
in many of the wound healing processes. It not only serves as
a chemotactic factor for leukocytes and ﬁbroblasts but also
stimulates ﬁbroblast diﬀerentiation into myoﬁbroblasts and
promotes angiogenesis [44, 45].
IL-8isaproinﬂammatorycytokinethatisupregulatedby
diﬀerent cellular stress stimuli [46]. Human cells are charac-
terized by their marked capacity for varying the expression
levels of IL-8, allowing modulating the concentration of this
cytokine to control the degree of neutrophil inﬁltration in
the injured tissue [46]. The expression of IL-8 is regulated at
both transcriptional and posttranscriptional levels [47], and
the main MAPK pathways (p38, MEK1/2, and JNK) play a
signiﬁcantroleinthereleaseofIL-8duringtheinﬂammatory
process [46].
7.1.2. Enhancement of Corneal Wound Healing. The induc-
tion of IL-8 facilitates an early innate immune response to
infection in the corneal stroma and represents an elementary
defense mechanism in corneal wound healing [48]. It
enhances healing by rapidly chemoattracting leukocytes and
ﬁbroblasts into the wound site, stimulating the latter to
diﬀerentiate into myoﬁbroblasts. In turn, myoﬁbroblasts
are critical for wound contraction and closure and for the
production of extracellular matrix molecules, which leads to
development of granulation tissue [44].
The role of PDGF in corneal wound healing [49]a n dI L -
8-mediated neutrophil chemotaxis [50]h a sb e e np r e v i o u s l y
documented. It enhances healing by rapidly chemoattracting
leukocytes and ﬁbroblasts into the wound site [2], where
PDGF increases IL-8 chemokine secretion twofold in human
corneal ﬁbroblasts, indicating that IL-8 is involved in PDGF-
mediated corneal wound healing. Both human corneal kera-
tocytesandepithelialcellshavebeenshowntosynthesizeand
release IL-8 following cytokine stimulation and/or infection
[51].
7.1.3. Proliferation in Arthritis. IL-8 may be of clinical
relevance in psoriasis and rheumatoid arthritis. Elevated
concentrations are observed in psoriatic scales, and this may
explain the high proliferation rate observed in these cells. IL-
8 may be also a marker of diﬀerent inﬂammatory processes
[52].
IL-8 (and also IL-1 and IL-6) probably plays a role in the
pathogenesisofchronicpolyarthritissinceexcessiveamounts
of this factor are found in synovial ﬂuids [53]. The activation
of neutrophils may enhance the migration of cells into the
capillaries of the joints. These cells are thought to pass
throughthecapillariesandenterthesurroundingtissuesthus
causing a constant stream of inﬂammatory cells through the
joints [54].
7.1.4. Role in Myelodysplastic Syndrome. Human recombi-
nant IL-8 has shown that the lesion responsible for defective
functions of neutrophils in patients with myelodysplastic
syndrome can be restored without stimulating myeloid
progenitor cells. IL-8 may be able, therefore, to reduce
the risks of lethal infections in these patients without the
potential risk of stimulating leukemic clones [55].
7.1.5. Gastric Mucosal Injury and Cancer Progress. In the
human gastric mucosa, elevated levels of ROS are associated
with Helicobacter pylori infection [56], and it leads to oxida-
tive DNA damage in the gastric mucosa thereby contributing
to mucosal injury and promoting carcinogenesis [57, 58].
H. pylori infection is also associated with increased gastric
mucosal cytokine expression including IL-8 [59, 60]a n d
TNF-α [61, 62].
TNF-α is an endogenous mediator of proinﬂammatory
cytokine stimulation and can induce ROS [63] and stimulate
theinductionofvariousgenesinvolvedininﬂammation[64]
including IL-8. IL-8 is an important mediator of H. pylori-
associated neutrophil inﬁltration and gastric inﬂammation
[57]. ROS modulates IL-8 secretion in gastric epithelial cells,
suggesting that IL-8 gene expression in the gastric mucosa is
redox sensitive [65].
Although a regulatory role of TNF-α in epithelial cell
repairhasbeendescribed[66],itiswellestablishedthatTNF-
α stimulates IL-8 and contributes to epithelial cell injury and
apoptosis [63].
7.1.6. Increased BAL Fluid in ALI and COPD. In human
ALI (acute lung injury), neutrophil inﬁltration is an early
and important pathophysiological event, and IL-8 appears
to have an important role in mediating this process [67, 68].
ClinicalresearchdemonstratedincreasedIL-8levelsinserum4 International Journal of Inﬂammation
and BAL (bronchoalveolar lavage) ﬂuid of patients with
ALI [69, 70]. Increased BAL ﬂuid levels of IL-8 predicted
the development of ALI in at-risk patient populations and
are associated with increased mortality in patients with
ALI [71]. In animal models of ALI, administration of IL-8
antibody conferred protection [72]. IL-8 is also produced by
respiratory epithelium [26].
Studies involving alveolar macrophages, U937 cells,
isolated peripheral blood monocytes, and human whole
blood demonstrated that hyperoxia modulates IL-8 gene
expression [73]. Oxidant stress other than hyperoxia was
previously described to induce IL-8 expression in respiratory
epithelial cells. DeForge et al. [74] and Lakshminarayanan et
al. [75] hyperoxia alone had a minimal eﬀect on IL-8 gene
expression. However, combination of hyperoxia and TNF-a
synergistically increased IL-8 gene expression.
COPD (chronic obstructive pulmonary disease)c i g a r e t t e
smoke can also induce airway inﬂammation. It has been
shown to activate proinﬂammatory transcription factorsNF-
κB and activator protein (AP)-1 [76]a sw e l la st ou p r e g u l a t e
the expression of TNF-α and IL-8, proinﬂammatory media-
tors associated with COPD [77].
7.1.7. Prevention of Lung Epithelial Cells Injury. TNF-α levels
are markedly elevated in BAL ﬂuid from patients with
ARDS [78], and TNF-α levels are associated with increased
IL-8 levels. TNF-α is a major inducer of IL-8 expression
in lung epithelial cells [26]. Neutralizing IL-8 antibodies
prevented lung injury in animal models of lung disease,
indicating IL-8 is an important mediator of lung injury
[79, 80]. IL-8 gene expression is induced by a wide variety
of agents including cytokines, growth factors, bacterial and
viral products, oxidants, and others [81]. Induction of IL-
8 gene expression is subject to both transcriptional and
posttranscriptional regulation in a cell/tissue-and stimulus-
speciﬁc manner [46, 81].
In lung epithelial cells, TNF-α activates IL-8 promoter
activity via recruitment of NF-κBt oaT N F - α response ele-
ment consistent with a role for transcriptional mechanisms
in the induction of IL-8 gene expression in lung epithelial
cells [82].
7.1.8. Signalling in Cystic Fibrosis. IL-8 drives the inﬂamma-
tory response in cystic ﬁbrosis (CF) which is an autosomal
recessive disorder caused by mutations in the gene encoding
the cystic ﬁbrosis transmembrane conductance regulator
(CFTR) [83].
BAL ﬂuid in patients with CF contains increased levels
of proinﬂammatory cytokines and neutrophils. IL-8 levels
attribute to activate NF-κB[ 84]. Prostaglandin E2 (PGE-2)
is a potent mediator of inﬂammation produced by cycloox-
genation of arachidonic acid, and its hypersecretion results
in elevated IL-8 secretion through unidentiﬁed signaling
pathway [85].
In human T lymphocytes, PGE-2 induces C/EBP homol-
ogous protein (CHOP) transcription factor that binds to
the IL-8 promoter [85]. CHOP is a growth arrest and DNA
damage-inducible gene 153 (GADD153) protein. PGE-2
mediates the IL-8 inﬂammatory response in CF cells through
the CHOP transcription factor. The inﬂammatory response
in CF contributes to neutrophil-driven lung destruction [86,
87]. Several cytokines, such as IL-1b, TNF-α,I F N - δ,a n d
bacterial products, induce IL-8 release from airway epithelial
cells [88], thus exacerbating the baseline inﬂammatory
milieu in CF.
Much of the PGE-2 in airways is likely to be derived from
theepithelium[89],andthestimulationofchloridesecretion
in airway epithelial cells by proinﬂammatory mediators such
as bradykinin (BK) occurs through the induced release of
PGE-2 (26). Moreover, BK induces IL-8 secretion in non-CF
and CF human airway epithelia [90].
The physiologic as well as pathologic concentrations up
to 100mM PGE-2 upregulate endogenous IL-8 expression
in human intestinal epithelial cells [91] and enhance IL-8
production in human synovial ﬁbroblasts stimulated with
IL-1b [92].
7.1.9. Increased Expression in Asthma. IL-8 plays an impor-
tantroleininﬂammatorylungdiseaseslikebronchialasthma
or severe infections caused by respiratory syncytial virus
(RSV), and during infancy it might lead to the develop-
ment of recurrent wheezing and/or bronchial asthma [93].
Increased concentrations of IL-8 are found in the BAL ﬂuid
and sputum of asthmatic patients [13]. In addition, repeated
administration of IL-8 into the airways induces bronchial
hyperreactivityinguineapigs[94].GeneticassociationofIL-
8 hasbeen described withasthma[95] and RSVbronchiolitis
[96].
IL-8 binds with high aﬃnity to two diﬀerent receptors:
IL-8 receptor α (IL-8RA, CXCR1) and β (IL-8RB, CXCR2).
These closely related proteins are members of the super fam-
ily of receptors, which couple to guanine nucleotide-binding
proteins. IL-8RA is localized on chromosome 2q35 [13],
wherelinkagetototalserumIgElevelsinasthmaticshasbeen
described [94]. Association of IL-8RA polymorphisms has
recently been described with asthma and chronic obstructive
pulmonary disease [95]. However, IL-8RA polymorphisms
donotplayamajorrole,neitherinthedevelopmentofsevere
RSV infections nor in asthma.
7.1.10. Increased Expression in the Colon Mucosa with Inﬂam-
matoryBowelDisease. IL-8isproducedinthecoloniclamina
propria of patients with inﬂammatory bowel disease.
T h e r ei sn od i ﬀerence in IL-8 protein concentrations
between inﬂamed mucosa of patients with Crohn’s disease
or ulcerative colitis. IL-8 does thus not permit the diﬀer-
entiation between these two diseases entities. Mucosal IL-8
protein and IL-8 mRNA concentrations are correlated with
thedegreeofinﬂammation.IL-8mRNAisstronglyexpressed
by intestinal inﬂammatory cells but not by intestinal epithe-
lial cells suggesting that virtually all IL-8 is produced by
interstitial inﬂammatory cells [96].
An imbalance of the intestinal immune system with a
shift towards proinﬂammatory mediators is a characteristic
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proinﬂammatory cytokines, IL-8 together with IL-l and
tumour necrosis factor play an important part.
IL-8 is synthesised by various colonic cancer cell lines
like HT-29 cells or Caco-2 cells [98]. Evidence has also been
provided that isolated normal intestinal epithelial cells may
synthesise IL-8 [98].
An increased synthesis of IL-8 has been described in
the mucosa of patients with inﬂammatory bowel disease.
Where Mahida and coworkers [99] found enhanced mucosal
tissue concentrations of IL-8 essentially only in patients with
ulcerativecolitisbutnotinpatientswithCrohn’sdisease,Izzo
et al. [100] detected increased concentrations of IL-8 also in
the colonic mucosa from patients with Crohn’s disease.
7.1.11. Promotion of Endometriosis Pathogenesis. IL-8 is rep-
resentative of α-chemokine group and is a chemotactic and
angiogenic factor [101]. It acts as an endometrial autocrine
and paracrine factor and regulates many physiologic pro-
cessessuchasmenstruationandremodelingofendometrium
[102]. In addition, IL-8 also contributes to the pathogenesis
ofendometriosisbypromotingaviciouscycleofendometrial
cell attachment, invasion, immune protection, cell growth,
and further secretion [103].
The presence of inﬂammation and neovascularization
observed in and around ectopic endometrial implants and
the presence of inﬂammatory neutrophils in these lesions
[104]i sc o m p a t i b l ew i t ht h eb i o l o g i c a la c t i o n so fI L - 8[ 105].
IL-8 is detectable in the peritoneal ﬂuid of most women with
an active ovarian cycle, and it is a normal constituent of
peritoneal ﬂuid in women with and without endometriosis.
The concentration of IL-8 in the peritoneal ﬂuid was higher
in women with endometriosis compared to women without,
and that diﬀerence was statistically signiﬁcant as has been
reported previously [106, 107].
Peripheral blood macrophages from endometriosis
patients produced increased concentrations of IL-8 [101]. In
women with early endometriosis (American Fertility Society
Stage 1), IL-8 concentrations is much high as compared to
women with later stages of the disease. It can be speculated
that this may implicate IL-8 in the induction of the disease,
and it is conceivable that other chemokines participate in
the chronic phase of endometriosis. There are a number
of potential cellular sources of IL-8 in endometriosis.
Enhanced production by peritoneal macrophages has been
found [107], but normal endometrial gland cells [108]a n d
stromal cells [109] also produce IL-8 that can be enhanced
by proinﬂammatory mediators. In normal nonpregnant
endometrium, IL-8 was found to be localized perivascularly
[102],suggestiveofadirectroleuponendothelialcellsaswell
as a function in presenting a ﬁxed chemotactic stimulus to
circulating leukocytes.
7.1.12. Intervertebral Disc Causing Low Back Pain. Human
NP (nucleus pulposus) produces IL-8. Signiﬁcant quantities
of IL-6, IL-8, and PGE2 were produced by both the sciatica
and low back pain groups.
Burke et al. studied the production of inﬂammatory
mediators in disc tissues in a similar group of patients
[110] and compared the levels of IL-6, IL-8, and PGE2
in their disc tissue from patients undergoing discectomy
for sciatica with those from patients undergoing fusion for
discogenic low back pain which showed that more IL-6, IL-
8, and PGE2 are produced by discs from patients with low
back pain compared with discs from patients with sciatica.
There was a trend towards less exposure of the NP in the
group with low back pain only compared with those with
sciatica introducing a bias towards higher levels of mediator
production in the latter [111].
The rates of production of IL-6 and IL-8 in the AI and
EXT categories of discs in low back pain are much higher
than those found in those with sciatica. A combination
of the innervation of the NP and increased production of
proinﬂammatory mediators suggests that the mechanism
for discogenic low back pain may be the induction of
hyperalgesia in the newly innervated degenerating NP. Both
IL-8 and PGE2 are known to induce hyperalgesia [112].
7.2. IL-8 and Cancer. The extensive eﬀects of increased IL-8
activity on tumor pathogenesis make it a unique therapeutic
target in cancer therapy. For example, IL-8 promotes tumor
growth, angiogenesis, and metastasis in murine models of
several cancers [113]. Moreover, blocking IL-8 activity with
a monoclonal antibody has been shown to decrease tumor
growth in two murine cancer models [114]. Blockade of IL-8
expression in some human melanoma cell lines by antisense
RNA has shown that IL-8 functions as an autocrine growth
modulator for these cells [33].
7.2.1. High Expression in Ovarian Cancer. IL-8 is expressed
at high levels in ovarian cancer cells where expression is
correlated with tumorigenicity [115]. IL-8 is overexpressed
in most human cancers, including ovarian carcinoma [116].
Induction of IL-8 expression is mediated primarily by the
transcription factor NF-κB[ 117]; however, the Src/signal
transducer and activator of transcription 3 (Stat3) path-
ways may also promote IL-8 production independent of
NF-κB[ 118]. High tumor IL-8 expression is signiﬁcant
in ovarian cancer associated with advanced tumor stage
and high-tumor grade. The higher the IL-8, the poorer
the survival rate. IL-8 overexpression in ovarian cancer
is associated with decreased patient survival and is an
independent prognostic factorforpoor clinical outcomethat
targeted therapy with IL-8 siRNA-DOPC in combination
withchemotherapyeﬀectivelyreducedtumorgrowthinboth
chemotherapy-sensitive and chemotherapy-resistant ovarian
cancer models [119]. these antitumor eﬀects are likely due
to a reduction in proangiogenic factors present in the tumor
microenvironment that led to decreased angiogenesis and
tumor cell proliferation following silencing IL-8 expression.
IL-8 may be a potential therapeutic target in ovarian cancer.
IL-8 overexpression is reported in multiple malignancies and
is frequently associated with poor clinical outcome [120].
Several studies have examined the utility of IL-8 as a
diagnostic or prognostic marker in patients with ovarian
cancer [121–123]. For example, increased IL-8 expression
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ovarian cancer patients is found to be associated with high-
grade and advanced-stage cancers, as well as with decreased
disease-related patient survival [121, 123]. Collectively, these
data provide the rationale for targeting IL-8 as a therapeutic
approach in ovarian carcinoma.
Decrease in IL-8 expression, especially when combined
with taxane-based chemotherapy, led to a statistically signif-
icant reduction in orthotopic tumor growth. Xu and Fidler
[36]reportedthatIL-8overexpressionwasdirectlyassociated
withincreasedtumorvascularityandtumorcellproliferation
in ovarian carcinoma.
7.2.2. Enhancement of Cancer Mechanism in Melanoma.
In melanoma, increased IL-8 levels are associated with
increased tumor angiogenesis; conversely, a reduction in
tumor microvessel density occurred following treatment
withananti-IL-8antibody[124].IL-8hasalsobeenshownto
increase tumor cell proliferation and to prolong the survival
of human endothelial cells and enhance their ability to form
tubules, which supports the theory that the proangiogenic
eﬀects of IL-8 are due to activation of both tumor and
endothelial cells [113, 124].
Members of the MMP family of proteins promote tumor
angiogenesis as well as cellular detachment, invasion, and
metastasis, and some MMP family members, including
MMP-2 and MMP-9, are reported to be regulated by IL-
8 expression [125, 126]. IL-8 induces MMP-2 and MMP-
9 expression in bladder cancer and melanoma cell lines,
which contributed to increased tumor cell invasion in vitro
[113, 126].
7.2.3. Increase of VEGF and Neuropilin Expression in Pancre-
atic Cancer. IL-8 is upregulated in both cancer and chronic
inﬂammatory diseases of the pancreas [127]. It is linked
to pancreatic cancer tumorigenesis primarily through its
regulation of angiogenesis and metastasis [120]. Human
umbilical vein endothelial cells (HUVECs) proliferation
and angiogenesis are both increased when cocultured with
pancreatic cancer cells, or with exogenous in IL-8. The
increaseofcellproliferationandangiogenesisofHUVECcan
be blocked by IL-8-neutralizing antibodies [128].
IL-8 is associated with chronic diseases of the pancreas
[127]. It is overexpressed in most human pancreatic cancer
tissues [120]. Higher IL-8 levels in pancreatic cancer patient
serum are associated with signiﬁcant weight loss [129].
The expression levels of IL-8 appear to correlate with
their tumorigenic and metastatic potential in an orthotopic
xenograft model [130]. Furthermore, treatment with exoge-
nous IL-8 increases the invasiveness of human pancreatic
cancer cell, while blocking IL-8 inhibited the growth of
another human pancreatic cancer cell [131]. Blocking IL-8
in pancreatic cancer cells decreased their growth and their
ability to attach to endothelial cells, suggesting that IL-8 is an
autocrine mitogenic factor important for metastasis [132].
The expression of IL-8 can be induced by many stim-
uli including lipopolysaccharide, phorbol 12-myristate 13-
acetate (PMA), IL-1, and TNF. Several stress factors, such as
hypoxia, acidosis, nitric oxide (NO), and cell density, also
signiﬁcantly inﬂuenced the production of IL-8 in human
pancreatic cancer cells [133].
IL-8 is involved in cancer hypoxia pathway where its ex-
pression is regulated by hypoxia-inducible factor-1 (HIF-1),
NF-κB, and KRAS [128]. IL-8 overexpressed in pancreatic
cancer increases MMP-2 activity and plays an important
role in the invasiveness of human pancreatic cancer [130,
131, 134], and human pancreatic cancer is associated with
increased expression of IL-8 [127].
IL-8 as a proantigenic cytokine that helps the spread
of distant metastasis by neovascularization and promotes
the survival of the tumor mass in general by maintaining a
rich capillary network to accommodate the heavy nutrient
requirements of this aggressive cancer. Blocking IL-8 and
IL-8 receptor CXCR2 signiﬁcantly inhibited angiogenesis
[118, 135].
Both IL-8 and VEGF are important components in
cellular response to hypoxia, a common event in cancer,
including human melanoma, colon cancer, and pancreatic
cancer [117]. IL-8 acts as a direct growth and survival
factor on pancreatic cancer cells, and IL-8 as multifaceted
regulator of gene expression can regulate multiple pathways
including angiogenesis, metastasis, and response to hypoxia
in pancreatic cancer [136].
7.2.4. Expression in the Neuroendocrine and Nonneuroen-
docrine Compartments of Prostate Cancer. Moore et al.
demonstrated that IL-8 is a positive regulator of tumor
formation in severe combined immunodeﬁciency (SCID)
in mice injected with the prostate cancer cell line PC-3
[137]. Patients with PC (prostate cancer) have high serum
levels of IL-8 which correlates with the stage of the disease.
Additionally, in PC serum IL-8 levels have been determined
to be an independent prognostic variable from the serum
levels of free and total prostate-speciﬁc antigen (PSA) [138].
The combined use of free and total PSA ratio and IL-8
levels has been found to be more accurate in distinguishing
between prostate cancer and benign prostatic hypertrophy.
In PC, serum IL-8 levels increase with progression of the
disease [139]. The PC cell line 3 expresses and secretes IL-8
[140]andexpressesIL-8receptorsCXCR1andCXCR2[140].
IL-8 is a mitogenic [21] and angiogenic factor [141]. PC cell
line LNCaP does not express IL-8, but selection of the cells in
androgen-deprived media led to the emergence of a cell line
thatproducesIL-8andismoretumorigenicthantheparental
cells [141].
The IL-8 receptor CXCR1 is rarely expressed in benign
epithelial cells, its expression is increased in PIN (pancreatic
invasive neoplasm), and further increase in invasive tumor
suggests paracrine mechanism where IL-8 produced by the
NE tumor cells may promote the proliferation of the non-
NE tumor cells in the absence of androgen [142].
7.2.5. Metastatic Factor in Breast Cancer. Estrogen receptor
(ER) status is an important parameter in breast cancer
management as ER-positive breast cancers have a better
prognosis than ER-negative tumors. IL-8 is overexpressed in
most ER-negative breast, ovary cell lines, and breast cancer,International Journal of Inﬂammation 7
whereas no signiﬁcant IL-8 levels are found in ER-positive
breast or ovarian cell lines. IL-8 is considered as a potential
metastatic factor in breast cancers [38]. IL-8 is found not
only in normal but also in cancerous breast [37, 143].
Metastasis represents the major remaining cause of
mortality in human breast cancer, which suggests that
invasiveness is associated with lack of ER and changes in IL-8
expression. However, there was no correlation between ERβ
expression and IL-8 level, indicating ERα, the main estrogen
receptor in ER-positive breast and ovarian cancer cells, is the
receptor linked to IL-8 expression. Patients with recurrent
prostate, breast, or ovarian cancer exhibit higher levels of IL-
8 in serum or peripheral blood leukocytes [138, 144, 145]
and in cancer tissues [34]. Several studies show that IL-8
expression in breast tumors is identical between normal and
cancer tissue [146, 147].
Concerning IL-8 receptors, CXCR1 expression is
extremely low in all lines, whereas most of the cells show a
nice expression of CXCR2, without any correlation with ER
status [143]. CXCR1 and CXCR2 which are encoded by two
distinct genes [148, 149] are expressed in most cancer cells
with no apparent correlation with the grade of the tumor
[150, 151].
Exogenous expression of IL-8 increases by twofold the
invasion rate of ER-positive breast cancer cells, without
aﬀecting the in vitro proliferation rate of these cells which
is the proinvasive role of IL-8. When IL-8 is transfected
in cancer cells, both tumor inhibition [152, 153]a n d
promotion [126, 154]h a v eb e e no b s e r v e din vivo depending
on the cell type [155].
7.2.6. BEV (Epstein Barr Virus) and NPC (Nasopharyngeal
Tumor). Several chemokines secreted from EBV-infected
NPC cells are increased upon EBV reactivation into the lytic
cycle, and IL-8 is upregulated most signiﬁcantly [156].
T h em o s tf r e q u e n th i s t o l o g i c a lt y p eo fN P Ci sc l o s e l y
associated with Epstein-Barr virus (EBV) infection [157].
NPC exhibits several inﬂammatory features in the tumor
tissues, including intensive leukocyte inﬁltration, abun-
dant expression of inﬂammatory cytokines, and consti-
tutive activation of inﬂammation-associated transcription
factors [158]. Expression of several chemokines has been
demonstrated in NPC tumors, including IL-8, macrophage
inﬂammatory proteins (MIPs), macrophage chemoattrac-
tant proteins (MCPs), and RANTES [159].
EBV reactivation in NPC cells is associated with the
induction of certain chemokines where IL-8 was upregulated
most signiﬁcantly and consistently [147].
Neutrophils ﬁrst invoke into inﬂamed tissues, then they
produce a variety of chemokines with potentials to direct
sequential recruitment of other leukocytes [160]. Therefore,
by initial recruitment of neutrophils, IL-8 may trigger the
subsequent inﬂux of leukocytes in NPC. Notably, neutrophil
inﬁltration promoted by tumor-derived IL-8 has been linked
to the poor prognosis of bronchioloalveolar carcinoma and
to increased genetic instability of Mutatect tumors [161],
suggesting that IL-8-attracted neutrophils may contribute to
tumorigenesis.
IL-8isassociatedwiththelevelofvascularizationinNPC
[159, 162]. Moreover, NPC is a highly metastatic cancer, and
IL-8 may be involved in the phenotype since it can promote
tumor invasion or metastasis through induction of certain
metalloproteinases [154].
IL-8 is a converged target gene of gammaherpesviruses
in both latent and lytic infection states. EBV utilizes the
lytic protein Zta and the latent protein LMP1 to induce IL-
8 expression, while Kaposi’s sarcoma-associated herpesvirus
(KSHV)canupregulateIL-8byeitherthelyticproteinK15or
thelatentproteinK13[163].SinceKSHV-associatedKaposi’s
sarcoma also exhibits several inﬂammation-like features,
inductionofIL-8islikelytobecriticalforthevirus-mediated
“inﬂammatory tumorigenesis”; [159, 162].
Blockage of IL-8 or IL-8 receptors may be considered
a potential therapeutic approach for treating NPC or other
inﬂammation-related malignancies [156].
8. Conclusion
IL-8, a potent angiogenic, proinﬂammatory, growth-pro-
moting factor, properties which may be shared by other
chemokines [164], is also a chemoattractant for neutrophils
and induces expression of several cell adhesion molecules
[164]. It also lead to neutrophil activation [165]a n d
hence might contribute to the pathogenesis of inﬂammatory
diseases. IL-8 speciﬁcally chemoattracts several cell types,
which is the basis for inﬂammation. Neovascularization is a
crucial step in tumor growth and metastasis. Regulation of
IL8 production is a key mediator of inﬂammation by NF-κB.
The receptors for IL-8 are widely expressed on normal and
various tumor cells.
IL-8 induces proinﬂammatory, chemotactic, and matrix,
degradative responses in many pathologies. More research
will certainly help to achieve a much better understanding
of the function of IL-8 in diﬀerent pathologies. However,
knowledge gained from IL-8 data might be applied in a
foreseeable future to cure the low back pain that often
accompanies disc degeneration and therefore be beneﬁcial
for the patient. Despite exciting advances on IL-8, signiﬁcant
t e c h n i c a lo b s t a c l e ss t i l lh a v et ob eo v e r c o m eb e f o r es u c h
approaches become realistic alternative therapeutic options
to conventional surgical intervention procedures. Studies to
understand IL-8 gene expression in the various cell types
may lead to new therapeutics to enhance or inhibit IL-8
production. Many outstanding questions regarding IL-8 and
inﬂammation exist. Further examination pin pointing the
role of diﬀerent IL-8 expressing subsets willallow us to better
understand this cytokine.
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